跳至主要内容
临床试验/CTRI/2014/04/004516
CTRI/2014/04/004516招募中4 期

Comparative study for efficacy and safety of Paclitaxel with Platinum analogue versus 5-Fluorouracil with Platinum analogue in resectable carcinoma esophagus

Tata Memorial Hospital0 个研究点目标入组 350 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
350

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Inclusion Criteria:
  • 1.Histologic confirmation of pathology: Squamous cell or adenocarcinoma of ca esophagus or GE junction.
  • 2.Age 18 years or older
  • 3.Eastern Cooperative Oncology Group performance status of 0 to 2
  • 4.Adequate bone marrow, hepatic, renal, and pulmonary function
  • 5.Willingness to provide written informed consent.

排除标准

  • Exclusion criteria shall be:
  • 1.Prior therapy for carcinoma esophagus or GE junction
  • 2.Evidence of distant metastases
  • 3.Received any of the investigational product in the last 30 days
  • 4.Patients who were pregnant or lactating
  • 5.Patients with uncontrolled or severe cardiovascular disease
  • 6.Pre-existing neurotoxicity greater than National Cancer Instituteâ??Common Toxicity Criteria (NCI-CTC) grade 2

研究者

相似试验